Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer.
circulating biomarkers
colorectal cancer
extracellular vesicles
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Mar 2022
07 Mar 2022
Historique:
received:
07
02
2022
revised:
28
02
2022
accepted:
05
03
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
11
3
2022
Statut:
epublish
Résumé
Colorectal cancer (CRC) is one of the most incident and lethal malignancies worldwide. Recent treatment advances prolonged survival in patients with metastatic colorectal cancer (mCRC). However, there are still few biomarkers to guide clinical management and treatment selection in mCRC. In this study, we applied an optimized flow cytometry protocol for EV identification, enumeration, and subtyping in blood samples of 54 patients with mCRC and 48 age and sex-matched healthy controls (HCs). The overall survival (OS) and overall response rate (ORR) were evaluated in mCRC patients enrolled and treated with a first line fluoropyrimidine-based regimen. Our findings show that patients with mCRC presented considerably higher blood concentrations of total EVs, as well as CD133+ and EPCAM+ EVs compared to HCs. Overall survival analysis revealed that increased blood concentrations of total EVs and CD133+ EVs before treatment were significantly associated with shorter OS in mCRC patients (
Identifiants
pubmed: 35267665
pii: cancers14051357
doi: 10.3390/cancers14051357
pmc: PMC8909146
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Progetti di Ricerca di Interesse Nazionale (PRIN)
ID : 2017EKMFTN_005
Références
JAMA Oncol. 2015 Sep;1(6):787-95
pubmed: 26181239
Int J Mol Sci. 2020 Dec 23;22(1):
pubmed: 33374539
World J Gastroenterol. 2013 May 7;19(17):2603-11
pubmed: 23674867
Oncotarget. 2017 Dec 22;9(70):33403-33415
pubmed: 30279970
J Neurooncol. 2016 Apr;127(2):391-400
pubmed: 26746692
Cancers (Basel). 2021 Feb 03;13(4):
pubmed: 33546102
Trends Biotechnol. 2020 Oct;38(10):1066-1098
pubmed: 32564882
Eur J Immunol. 2017 Oct;47(10):1584-1797
pubmed: 29023707
Int J Mol Sci. 2022 Jan 26;23(3):
pubmed: 35163305
BMJ. 2006 May 6;332(7549):1080
pubmed: 16675816
Nat Biomed Eng. 2021 Jul;5(7):678-689
pubmed: 34183802
Mol Cell Proteomics. 2013 Mar;12(3):587-98
pubmed: 23230278
Mol Cancer. 2013 Jun 14;12:62
pubmed: 23767874
Nat Rev Cancer. 2020 Dec;20(12):697-709
pubmed: 32958932
Biomedicines. 2021 Mar 09;9(3):
pubmed: 33803470
Nat Rev Clin Oncol. 2021 Aug;18(8):506-525
pubmed: 33864051
Int J Mol Sci. 2021 Apr 08;22(8):
pubmed: 33918012
Front Cell Neurosci. 2017 Mar 27;11:77
pubmed: 28396625
Front Cell Dev Biol. 2021 Oct 15;9:705791
pubmed: 34722499
Biochem Biophys Res Commun. 2008 Sep 5;373(4):567-71
pubmed: 18590703
Nat Rev Clin Oncol. 2018 Oct;15(10):617-638
pubmed: 29795272
Nat Rev Gastroenterol Hepatol. 2019 Feb;16(2):79-80
pubmed: 30575801
J Oncol. 2019 Nov 18;2019:5879616
pubmed: 31827511
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
PLoS One. 2012;7(12):e51862
pubmed: 23251644
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Genes (Basel). 2021 Feb 27;12(3):
pubmed: 33673461
Biomed Res Int. 2014;2014:173401
pubmed: 25061601
J Extracell Vesicles. 2016 Aug 29;5:31488
pubmed: 27576678
Br J Cancer. 2020 Mar;122(6):801-811
pubmed: 31937922
Clin Cancer Res. 2019 Jan 1;25(1):266-276
pubmed: 30287549
Cell Commun Signal. 2020 Oct 20;18(1):163
pubmed: 33081785
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77
pubmed: 26858453
Oncotarget. 2017 Jun 6;8(44):75952-75967
pubmed: 29100283
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
Am J Pathol. 2017 Jul;187(7):1633-1647
pubmed: 28619275
In Vivo. 2019 Jul-Aug;33(4):1279-1284
pubmed: 31280219
Mol Cancer. 2019 Mar 30;18(1):59
pubmed: 30925927
J Extracell Vesicles. 2020 Aug 26;9(1):1809765
pubmed: 32944195
Oncol Lett. 2011 Nov;2(6):1065-1071
pubmed: 22848268
Oncotarget. 2016 Nov 29;7(48):78698-78712
pubmed: 27659530
Signal Transduct Target Ther. 2021 Mar 8;6(1):109
pubmed: 33678805
J Exp Clin Cancer Res. 2016 Mar 25;35:54
pubmed: 27015840
J Clin Invest. 2008 Jun;118(6):2111-20
pubmed: 18497886
Chem Rev. 2018 Feb 28;118(4):1917-1950
pubmed: 29384376
Cell Commun Signal. 2019 Jul 10;17(1):73
pubmed: 31291956
ACS Nano. 2018 Jan 23;12(1):671-680
pubmed: 29300458
Leuk Lymphoma. 2017 Jun;58(6):1424-1432
pubmed: 27739922
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Mol Sci. 2020 Oct 23;21(21):
pubmed: 33114229
FASEB J. 2019 Mar;33(3):4248-4260
pubmed: 30521383
Cancers (Basel). 2020 May 27;12(6):
pubmed: 32471160
J Clin Pathol. 2018 Feb;71(2):110-116
pubmed: 28942428
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6829-34
pubmed: 23569237
Mol Cancer Res. 2010 Aug;8(8):1105-15
pubmed: 20663862